Entering text into the input field will update the search result below

The Biotech Analyst Run Down For Tuesday

Jul. 07, 2020 9:20 AM ETKURA, NGM, NVAX, PCVX, UNUM2 Comments
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Hope isn't destiny. Left passive its nothing more than disappointment deferred” ― Bill Willingham,

Stocks started the first full trading week of the third quarter on the right foot on Monday.  A big rally in Chinese markets helped boost equities here.  The S&P 500 rose one and a half percent while the NASDAQ was up better than two percent on the day.

European markets are down today and our pre-market futures are down just over a half percent as equities look like they will open down to start a new trading day.

Latest Post From The Biotech Maven

Here are four biotech stocks analyst firms like this Tuesday.

Unum Therapeutics (UNUM) sees its first analyst activity since late in the first quarter today.  Wedbush upgrades the small cap name to Outperform from Neutral this morning.  The company just completed a small acquisition and raised just over $100 million from investors to do that purchase it should be noted.

Like Duh!: "Officials in Los Angeles, Seattle, and Miami-Dade County, Fla., have acknowledged that anti-police protests and riots may have led to increased spread of the coronavirus.   All three cities have experienced an uptick in coronavirus cases after weeks of protesting sparked by the death of George Floyd in Minneapolis police custody." 

Vaxcyte (PCVX) getting the usual post-IPO kisses from analysts this morning in the first analyst actions on this name since it came public in mid-June.  Jefferies ($41 price target), Needham ($40 price target) and Cantor Fitzgerald all initiate the shares as a new Buy this morning.

Image result for Don't ForgetDon't forget about this special offer from the Dividend Hunter. 50% OFF a full year subscription to one of the largest monthly dividend newsletters (over 10,000 subscribers). A ridiculously low $49 annually by clicking here.

Kura Oncology (KURA) is initiated as a new Outperform with a $27 price target at Credit Suisse which provides the following commentary.

Kura is now conducting a registration trial for tipifarnib with data expected around 2021, supporting a possible 2022 launch, and models peak revenue potential of $400M-$500M in the r/r HRAS overexpressing patients. The analyst also sees a very favorable reward/risk skew ahead of the first clinical update of KO-539 in NPM1 Mutant/MLL-r AM"

This Is The Lobbyist You Want! Novavax (NVAX), which has no recurring revenues after more than 20 years as a public company, scores $1.6 billion...yes billion with a B,  from the government as part of their Operation Warp Speed to develop a Covid19 vaccine.  There is no easier 'funding gate' than the one to taxpayer's money as an old friend like to quip.

Finally, we have NGM Biopharmaceuticals (NGM) which is initiated as a new Buy with a $40 price target over at Chardan Capital.

And those are four biotech stocks getting the 'thumbs up' before the bell on this Tuesday morning.

A man who catches History's eye is thereafter bound to a mistress from whom he will never escape.”― Salman Rushdie, Shame

Image result for Act Now

THIS WEEK ONLY If you join the The Biotech Forum by clicking HERE you will get our 'option play of the week', as well as access to our model portfolio, investment archives and a very active Live Chat area during the trading day. In addition, we are providing 14 day free trials this week only. This will also entitled you to 25% Off discount links to our sister services, The Busted IPO Forum and The Insiders Forum, at the end of the trial. Both model portfolios have crushed the returns of the Russell 2000 since their launches.

Thank You & Happy Hunting,

Bret Jensen

Founder, The Biotech Forum, The Busted IPO Forum & The Insiders Forum

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.